CSU secures $3.1 million from NIH to advance SolaVAX coronavirus vaccine research
Researchers at CSU have worked quickly and collaboratively to move this vaccine research forward.
Researchers at CSU have worked quickly and collaboratively to move this vaccine research forward.
As the world looks for ways to stop the spread of the new coronavirus, Colorado State University has activated a unique combination of national experts, facilities, and vaccine manufacturing capability to help in the fight.
John Wyckoff talks about a new research project to develop a human vaccine against the Rift Valley Fever virus.
John Wyckoff will oversee operations relating to CSU’s research expertise in translational medicine in the Infectious Disease Research Center.
BioMARC, the university's vaccine manufacturing facility, created material to be used in labs nationwide in the fight against Zika virus.
CSU’s vaccine manufacturing facility, BioMARC, is developing a drug to protect U.S. soldiers from a mosquito-borne pathogen that can cause severe illness and death.
Colorado State University’s Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC) has been awarded a 10-month, $4.6 million contract funded by the Department of Defense (DoD) to help develop and manufacture new vaccines to fight encephalitic viruses that cause inflammation of the brain.
BioMARC, a high-containment biopharmaceutical facility operated by CSU, is manufacturing the vaccines for the U.S. Department of Defense in support of human clinical trials.